

IN THE CLAIMS

Please substitute pending claims 32, 35, 36, 38, 39, 41-46, 48, and 49 with the corresponding amended claims, as shown below:

A1
32. (Amended) A method for improving the efficacy of a pharmaceutical useful for treating erectile dysfunction in a male subject, comprising:
percutaneously administering a pharmaceutically effective amount of a steroid in the testosterone synthetic pathway to the subject in a composition comprising at least one of a C1-C4 alcohol, the steroid, a thickener, and a penetration enhancer; and
administering the pharmaceutical to the subject.

Sub B5
A2
35. (Amended) The method of claim 32 wherein the pharmaceutical is at least one of sildenafil, citrate, pentoxifylline, yohimbine, apomorphine, alprostadil, papavaerine, phentolamine, and combinations, salts, and enantiomers thereof.

36. (Amended) The method of claim 32 wherein the pharmaceutical is sildenafil citrate.

A3
38. (Amended) The method of claim 37 wherein the fatty acid comprises an alkyl chain length of at least 12 carbon atoms.

39. (Amended) The method of claim 32 wherein the alcohol comprises at least one of ethanol, 2-propanol, n-propanol, and mixtures thereof.

Sub B6
A4
41. (Amended) The method of claim 39 wherein the composition comprises about 1.0 % w/w of testosterone.

42. (Amended) The method of claim 39 wherein the enhancer comprises about 0.5% w/w of isopropyl myristate.

43. (Amended) The method of claim 39 wherein the thickener is polyacrylic acid.

44. (Amended) The method of claim 32 wherein the steroid comprises about 0.5% to about 5.0% w/w testosterone, the thickener comprises about 0.10% to about 2% w/w of polyacrylic acid, the enhancer comprises about 0.1% to about 2% w/w of isopropyl myristate, the C1-C4 alcohol comprises about 40.0% to about 90% w/w of ethanol. ✓

45. (Amended) The method of claim 32 wherein the subject is hypogogadal.

46. (Amended) The method of claim 32 wherein the subject suffers from primary hypogonadism.

48. (Amended) The method of claim 32 wherein the subject is a man having a right/left upper arm/shoulder and an abdomen having a right and left side, and the administering comprises administering the composition to the right/left upper arms/shoulders and to the right/left sides of the abdomen once per day on alternate days.

49. (Amended) The method of claim 32 wherein the pharmaceutically effective amount of a steroid comprises about 75 mg of testosterone per day.

Please cancel claims 34 and 50, without prejudice, and add new claims 57-100 as follows:

57. (New) The method of claim 32 wherein the pharmaceuticals is apomorphine. OK

58. (New) The method of claim 32 wherein the composition is administered to the subject in an amount from about 2.5 g/day to about 10.0 g/day. G K

59. (New) The method of claim 32 wherein the composition administered to the subject achieves a maximum serum testosterone concentration at between about 16 hours and about 22 hours after administration of the composition. OK

60. (New) The method of claim 32 wherein the subject suffers from secondary hypogonadism. OK

61. (New) The method of claim 32 wherein the subject suffers from age associated hypogonadism.

Sub B10
62. (New) The method of claim 32 wherein in the composition is administered at least once per day.

63. (New) The method of claim 62 wherein the percutaneous administration is to back, abdomen, upper arm or thigh of the subject.

Sub B11
64. (New) The method of claim 63 wherein the administration is to same site for approximately 7 days.

65. (New) The method of claim 32 wherein the composition comprises about 0.1 g to about 10.0 g testosterone.

66. (New) The method of claim 65 wherein the composition comprises about 1.0 g testosterone.

67. (New) The method of claim 65 wherein the composition comprises about 0.1 g testosterone.

68. (New) The method of claim 32 wherein the composition comprises about 0.1 g to about 5.0 g polyacrylic acid.

69. (New) The method of claim 68 wherein the composition comprises about 0.9 g polyacrylic acid.

70. (New) The method of claim 32 wherein the composition comprises about 0.1 g to about 5.0 g isopropyl myristate.

71. (New) The method of claim 71 wherein the composition comprises about 0.5 g isopropyl myristate.

72. (New) The method of claim 32 wherein the composition comprises about 30.0 g to about 98 g ethanol.

73. (New) The method of claim 72 wherein the composition comprises about 72.5 g ethanol.

74. (New) The method of claim 32 wherein the steroid comprises about 0.5 g to about 5.0g testosterone, the thickener comprises about 0.10 g to about 2 g of polyacrylic acid, the enhancer comprises about 0.1 g to about 2 g w/w of isopropyl myristate, the C1-C4 alcohol comprises about 40.0 g to about 90 g w/w of ethanol. ✓

75. (New) The method of claim 32 wherein the composition comprises about 0.1% to about 10.0% w/w testosterone.

76. (New) The method of claim 75 wherein the composition comprises about 1.0% w/w testosterone.

77. (New) The method of claim 75 wherein the composition comprises about 0.1% w/w testosterone.

78. (New) The method of claim 32 wherein the composition comprises about 0.1% to about 5.0% w/w polyacrylic acid.

79. (New) The method of claim 78 wherein the composition comprises about 0.9% w/w polyacrylic acid.

80. (New) The method of claim 32 wherein the composition comprises about 0.1% to about 5.0% w/w isopropyl myristate.

Sub B12 Cont
81. (New) The method of claim 80 wherein the composition comprises about 0.5% w/w isopropyl myristate.

82. (New) The method of claim 32 wherein the composition comprises about 30.0% to about 98% w/w ethanol.

83. (New) The method of claim 82 wherein the composition comprises about 72.5% w/w ethanol.

84. (New) The method of claim 32 wherein the pharmaceutically effective amount of the steroid decreases mean follicle stimulating hormone serum level concentration in the subject.

further limit?

85. (New) The method of claim 32 wherein the pharmaceutically effective amount of the steroid decreases mean luteinizing hormone serum level concentration in the subject.

86. (New) The method of claim 32 wherein the pharmaceutically effective amount of the steroid is sufficient to achieve an erection for sexual intercourse in the subject.

87. (New) The method of claim 32 wherein the pharmaceutically effective amount of the steroid is sufficient to maintain an erection in the subject after penetration during intercourse.

Sub B13
88. (New) The method of claim 32 wherein the pharmaceutical is a phosphodiesterase inhibitor.

89. (New) The method of claim 88 wherein the phosphodiesterase inhibitor is at least one of type III, type IV, type V, and mixtures thereof.

90. (New) The method of claim 89 wherein the phosphodiesterase inhibitor is type V.

91. (New) The method of claim 90 wherein the phosphodiesterase inhibitor is administered to the subject in about a 50 mg dose.

Sub B13 cont

92. (New) The method of claim 90 wherein the phosphodiesterase inhibitor is administered about 20 minutes to about 60 minutes before sexual intercourse.

93. (New) The method of claim 88 wherein the phosphodiesterase inhibitor is administered in the form of at least one of a salt, ester, amide, prodrug, and mixtures thereof.

94. (New) The method of claim 32 wherein the pharmaceutically effective amount of the steroid restores nitric oxide activity to the subject. *See claim 84*

95. (New) The method of claim 32 wherein the composition further comprises at least one of a salt, emollient, stabilizer, antimicrobial, fragrance, and propellant.

Al

96. (New) The method of claim 32 wherein the penetration enhancer is at least one of an accelerant, adjuvant, sorption promoter and mixtures thereof.

Sub B14

97. (New) The method of claim 32 wherein the pharmaceutical is administered about 20 minutes to about 60 minutes before sexual intercourse.

98. (New) The method of claim 32 wherein the composition and the pharmaceutical are components of a kit.

99. (New) The method of claim 98 wherein the kit further comprises a set of instructions. *Non elect*

100. (New) A method for improving the efficacy of a pharmaceutical useful for treating erectile dysfunction in a male subject, comprising:

percutaneously administering a pharmaceutically effective amount of a steroid in the testosterone synthetic pathway to the subject in a composition comprising at least one of a C1-C4 alcohol, the steroid, a thickener, and a penetration enhancer; and

administering the pharmaceutical to the subject;
wherein the subject achieves hormonal steady state levels of testosterone.

NO further duplicate

32